We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Teneobio

News List

Amgen to Acquire Teneobio for $900M contractpharma
July 29, 2021
Includes Teneobio's bispecific and multispecific antibody technologies, heavy-chain only platform and T-cell engager platform.
AbbVie Exercises Right to Acquire TeneoOne and TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma americanpharmaceuticalreview
June 25, 2021
AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma ...
Kite licences Teneobio’s multiple myeloma targeting antibodies pharmaceutical-technology
April 06, 2020
Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to antibodies intended for the treatment of multiple myeloma.
AbbVie and Teneobio to co-develop new drug for multiple myeloma pharmaceutical-technology
February 13, 2019
AbbVie has entered a strategic collaboration with biotechnology company Teneobio and its affiliate TeneoOne for the development and commercialisation of a multiple myeloma candidate TNB-383B.....